

Summary of Consolidated Financial Results for the Year Ended March 31, 2026

[IFRS]

May 11, 2026

Company name: **TEIJIN LIMITED** (Stock code 3401) <https://www.teijin.com>
 Stock exchange listing: Tokyo (Prime Market)
 Representative: Akimoto Uchikawa
 President and CEO
 Contact person: Tetsuji Mikami
 General Manager, Corporate Communication Department
 Telephone number: +81-(0)3-3506-4395
 Scheduled date for dividends payment: May 29, 2026
 Availability of supplementary information for the financial results: Yes
 Organization of briefing on the financial results: Yes (for analysts and institutional investors)

(Amounts rounded to the nearest Millions of yen)

1. Highlight of FY2025 (April 1, 2025 through March 31, 2026)

(1) Consolidated financial results

(Percentages are year-on-year changes)

	Revenue		Adjusted operating income		Operating income (loss)		Profit (Loss) before tax	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
FY2025	873,190	(13.2)	25,781	(6.6)	(70,714)	—	(74,060)	—
FY2024	1,005,471	4.7	27,594	25.7	(71,828)	—	(78,038)	—

	Profit		Profit attributable to owners of parent		Comprehensive income(loss)	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
FY2025	(87,920)	—	(88,003)	—	(57,133)	—
FY2024	30,310	—	28,347	—	29,055	7.9

Note: Share of profit of investments accounted for using the equity method FY2025: 1,960 million yen (FY2024: 1,052 million yen)

※Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

	Basic earnings per share	Diluted earnings per share	Return on equity
	Yen	Yen	%
FY2025	(456.33)	(456.33)	(22.1)
FY2024	147.15	147.15	6.7

	Return on assets	Adjusted operating income ratio
	%	%
FY2025	(7.5)	3.0
FY2024	(6.8)	2.7

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent	Equity attributable to owners of parent per share
	Millions of yen	Millions of yen	Millions of yen	%	Yen
As of March 31, 2026	920,115	368,631	364,461	39.6	1,889.22
As of March 31, 2025	1,061,272	438,541	431,378	40.6	2,238.40

(3) Consolidated cash flows

	From operating activities	From investing activities	From financing activities	Cash & cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
FY2025	98,654	(38,956)	(73,251)	104,474
FY2024	69,843	52,517	(134,459)	107,538

2. Dividends

Period	Dividends per share				
	1Q	2Q	3Q	4Q	Annual
	Yen	Yen	Yen	Yen	Yen
FY2024	—	25.00	—	25.00	50.00
FY2025	—	25.00	—	25.00	50.00
FY2026 (outlook)	—	25.00	—	25.00	50.00

Period	Total dividends paid (Annual)	Payout ratio (Consolidated)	Ratio of dividends to equity attributable to owners of parent (Consolidated)
	Millions of yen	%	%
FY2024	9,635	34.0	2.3
FY2025	9,645	—	2.4
FY2026 (outlook)		21.4	

3. Forecast for Operating Results in the Fiscal Year Ending March 31, 2027 (FY 2026)

(Percentages are year-on-year changes)

	Revenue		Adjusted operating income		Operating income		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
FY2026	850,000	(2.7)	30,000	16.4	70,000	—	45,000	—	233.26

■ Notes

(1) Significant changes in the scope of consolidation: Yes

Newly included: None

Excluded: 2 companies (Teijin Nakashima Medical Co., Ltd., Teijin Automotive Technologies NA Holdings Corp.)

(2) Changes in accounting policies or changes in accounting estimates

- a. Changes in accounting policies required by IFRS: None
- b. Changes in accounting policies due to other reasons: None
- c. Changes in accounting estimates: None

(3) Number of shares issued (common shares)

a. Shares issued (including treasury shares) at the end of period

As of March 31, 2026: 197,953,707 shares

As of March 31, 2025: 197,953,707 shares

b. Treasury shares at the end of period

As of March 31, 2026: 5,037,805 shares

As of March 31, 2025: 5,236,834 shares

c. Average shares outstanding during the period

FY2025: 192,850,305 shares

FY2024: 192,644,994 shares

Reference: Non-consolidated Financial Results of FY2025 (April 1, 2025 through March 31, 2026)

(1) Non-consolidated financial results

(Percentages are year-on-year changes)

	Net sales		Operating income(loss)		Ordinary income		Net income(loss)	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
FY2025	115,659	1.1	(8,984)	—	38,349	470.9	(8,159)	—
FY2024	114,455	(13.4)	(10,924)	—	6,718	(91.0)	(56)	—

	E.P.S.	Diluted E.P.S.
	Yen	Yen
FY2025	(42.31)	—
FY2024	(0.29)	—

(2) Non-consolidated financial position

	Total assets	Net assets	Shareholders' equity Ratio	Shareholders' equity per share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2026	539,644	264,244	48.9	1,369.19
As of March 31, 2025	599,697	283,919	47.3	1,472.40

'cf. Shareholders' equity as of March 31, 2026 : 264,139 million yen (As of March 31, 2025 : 283,757 million yen)

- Review by certified public accountants or an audit firm for the attached quarterly consolidated financial statements:
None

- Appropriate use of forecast and other information and other matters

(Caution regarding all forecasts in this document)

All forecasts in this document are based on management's assumptions in light of information currently available and involve certain risks and uncertainties. Actual results could differ materially from these forecasts. For information on these forecasts, refer to "Outlook for FY2026", beginning on page 6.

Supplementary Information

Table of Contents

1. Overview of business results, etc.	2
(1) Overview of the business results for the period under review	2
(2) Analysis of Assets, Liabilities and Equity	5
(3) Analysis of Cash Flows	5
(4) Outlook for FY2026	6
2. Basic Policy on Selection of Financial Reporting Standards	8
3. Consolidated Financial Statements and Notes Thereto	9
(1) Consolidated Statements of Financial Position	9
(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income	11
(3) Consolidated Statements of Changes in Equity	13
(4) Consolidated Statements of Cash Flows	17
(5) Notes to the Consolidated Financial Statements	19
(Going Concern Assumptions)	19
(Segment Information)	19
(Impairment of Non-Financial Assets)	23
(Earnings Per Share)	24
(Significant Subsequent Events)	25

1. Overview of business results, etc.

(1) Overview of the business results for the period under review

1) Overview

In FY2025, amid persisting geopolitical risks and the uncertainty that involves trade and industry policy remaining at a high level, the world economy continued to show mixed landscapes in terms of business confidence, depending on regions on the back of the differences in financial policy and trends of demand. While consumer spending remained strong in the United States on the back of the robust employment environment, the trend of recovery was limited in Europe, centering on the manufacturing industry, due to the prolonged high interest rate environment and sluggish demand from abroad. In China, a delay in recovery of domestic demand continued to weigh on the economy. Under these circumstances, the macroeconomic environment remains uncertain due to the situations in which corporate activities are affected by the fluctuations in foreign exchange rates, changes in energy and raw material prices, and the policy trends of various countries.

For FY2025, the Group's revenue declined 13.2% year on year to 873.2 billion yen, and adjusted operating income (Note) stood at 25.8 billion yen, a decrease of 6.6% year on year. Operating loss was 70.7 billion yen (ref.: operating loss of 71.8 billion yen for the previous fiscal year) mainly due to the recording of impairment losses in the aramid business and the Healthcare Business. Loss attributable to owners of parent was 88.0 billion yen (ref.: profit of 28.3 billion yen for the previous fiscal year). Adjusted operating income by segment decreased due to intensifying competition overall in the Materials Business Field and the influence of large-scale periodical maintenance in the aramid business. In the Fibers & Products Converting Business, sales volume was robust in general, while adjusted operating income decreased slightly. In the Healthcare Business, adjusted operating income increased mainly due to the increases in the number of rented home healthcare device and licensing fees.

As a result, ROE was -22.1%, and ROIC was 2.6%. EBITDA was 86.1 billion yen.

Note: Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses arising from nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

Please see below for the FY2025 business results by segment.

2) Overview of each business segment

- ① **Materials Business Field: Factors that contributed to income included profitability improvement in the composites business, and reduced depreciation and amortization as a result of the recording of impairment losses, etc. in the aramid business. On the other hand, the negative factors included the influence of large-scale periodical maintenance in the aramid business and the decline in facility operating rates due to the decrease in sales volume in the carbon fibers business on top of the reduced sales price under the intensified competitive environment. In light of these circumstances, the Group focuses on a cost structure reform in the aramid business and carbon fibers business, seeking drastic improvement of income.**

Revenue was 338.6 billion yen, a year-on-year decrease of 120.7 billion yen (26.3%), while adjusted operating income was 0.1 billion yen, a year-on-year decrease of 5.9 billion yen (98.0%). EBITDA was 20.7 billion yen, a decrease of 11.8 billion yen year on year, while ROIC was 0%.

Aramid business faced a delay in the recovery of European automobile markets and a delay in a client's project for ballistic protection applications. While sales volume increased as a result of sales expansion in industrial applications, the sales composition worsened, reflecting the increased ratio for the optical fiber applications, of which the price competition intensified. Additionally, while revenue increased, adjusted operating income decreased, which is attributable to the effect of a decrease in depreciation and amortization arising from impairment loss recorded at the end of the second quarter, which emerged in the second half of the current fiscal year, in addition to the decline in facility operating rates due to the large-scale periodical maintenance performed during the first quarter. The early recovery of the fundamental profitability is sought in the aramid business through the currently running drastic cost structure reforms.

In the resin and plastic processing business, sales volume of polycarbonate resin, which is one of the Group's major products, decreased, reflecting the sluggish economy in China and ongoing intensified competitive environment. While selling prices fell as a result of a decrease in raw materials prices, the spread remained unchanged in general. As a result of these factors, while revenue decreased on a year-on-year basis, adjusted operating income increased thanks to the effect of foreign exchange.

In the carbon fibers business, sales volume decreased and facility operating rates declined: for aircraft application due to continued constraints in the supply chain; and for industrial application, due to sluggish European economy and intensified competitive environment. Furthermore, selling prices mainly for general purpose products continued to fall, resulting in the year-on-year decreases in revenue and adjusted operating income. A drastic cost structure reform is also under way for the carbon fibers business to improve profitability, including temporary suspension of a plant in the United States.

In the composites business, factors that contributed to income included the improvement of profitability in the business in North America and reduced depreciation and amortization resulting from the recording of impairment losses in the previous fiscal year (The business in North America completed a transfer of shares effective July 1, 2025). In Europe, sales volume decreased due to a decline in demand for some models, reflecting the deceleration of automobile markets. As a result, revenue decreased and adjusted operating income increased on a year-on-year basis.

- ② **Fibers & Products Converting Business: While robust sales were recorded in both fields of fiber materials and apparel, and industrial materials, revenues and adjusted operating income slightly decreased on a year-on-year basis.**

Revenue was 350.1 billion yen, a decrease of 1.9 billion yen (0.5%) year on year, and adjusted operating income was 17.1 billion yen, a decrease of 0.7 billion yen (4.2%) year on year. EBITDA was 24.9 billion yen, a decrease of 0.6 billion yen year on year, while ROIC was 8%.

In the field of fiber materials and apparel, sales of textiles for the North American market and sales of apparel items in Japan remained robust. Sales of materials and products in China also contributed to operating performance significantly. In the field of industrial materials, sales of polyester staple fibers for filters and household merchandise sold through TV shopping programs remained strong, despite the influence of a delay in recovery of demand for the automotive application.

Furthermore, the Group has been preparing for a business combination of Teijin Frontier Co., Ltd. and Asahi

Kasei Advance Corporation in pursuit of sustainable growth and maximization of corporate value.

③ Healthcare Business: In the home healthcare device field, the number of rental device recorded robust growth. On the other hand, in the field of pharmaceuticals, although licensing fees contributed to income, it was affected by the widespread use of generic drugs and the revision of drug prices, etc.

Revenue was 138.6 billion yen, an increase of 1.6 billion yen (1.2%) year on year, while adjusted operating income was 13.4 billion yen, an increase of 7.7 billion yen (136.0%) year on year. EBITDA was 39.2 billion yen, an increase of 4.5 billion yen year on year, while ROIC was 7%.

In the home healthcare device field, as the number of examinations increased in the market for continuous positive airway pressure (CPAP) therapy, the number of new prescriptions continued to grow, and the number of rented CPAP devices steadily increased. Also, in the home oxygen therapy (HOT) market, the number of rented devices progressed steadily, and the number of rented new model of portable oxygen concentrators launched in 2023 increased.

In the field of pharmaceuticals, several licensing fees contributed to income. On the other hand, income was affected by the accelerated widespread use of generic drugs and the revision of drug prices in April 2025, mainly for drugs that remained on the National Health Insurance drug price list long after the expiration of patents. In November 2025, the Group launched YORVIPATH, a treatment for hypoparathyroidism.

Amortization arising from the impairment loss in the sales rights for the diabetes treatments decreased, and the effects of reduction in fixed costs relating to the progress of structural change emerged.

④ Others (including the battery materials & membrane field, the regenerative medicine & implantable medical device field, etc.)

Revenue was 46.0 billion yen, a decrease of 11.3 billion yen (19.7%) year on year, while adjusted operating income was 4.6 billion yen, a decrease of 2.5 billion yen (35.6%) year on year.

Stable revenue was secured in the battery materials & membrane field due to robust sales.

In the regenerative medicine field, the launch of CDMO business progressed steadily. In the implantable medical device field, the bioresorbable osteosynthesis materials business operated by TEIJIN MEDICAL TECHNOLOGIES CO., LTD. achieved steady growth. Teijin Nakashima Medical Co., Ltd., the artificial joint business operator, was excluded from the scope of consolidation due to sale of its shares.

(2) Analysis of Assets, Liabilities and Equity

Total assets at the end of the current consolidated fiscal year decreased by 141.2 billion yen from the end of the previous consolidated fiscal year to 920.1 billion yen. This decrease was primarily due to a decline in assets held for sale as a result of the transfer of shares in Teijin Nakashima Medical Co., Ltd. (hereinafter, "Teijin Nakashima Medical") and Teijin Automotive Technologies NA Holdings Corp. (hereinafter, "TAT"), as well as reductions in property, plant and equipment, and intangible assets resulting from depreciation and significant impairment losses.

Total liabilities decreased by 71.2 billion yen from the end of the previous consolidated fiscal year to 551.5 billion yen. This decrease was primarily due to the repayments of borrowings and a decline in liabilities directly associated with assets held for sale as a result of the transfer of shares in Teijin Nakashima Medical and TAT.

Total equity (including non-controlling interests) decreased by 69.9 billion yen from the end of the previous consolidated fiscal year to 368.6 billion yen, primarily due to the recognition of significant impairment losses.

As a result, the debt-to-equity ratio was 0.92 and the equity ratio was 39.6%. (As of end of the previous consolidated fiscal year, the debt-to-equity ratio was 0.9 and the equity ratio was 40.6%.)

The conversion rates of balance sheets at the end of the current consolidated fiscal year are 160 yen / US dollar, 183 yen / euro, and 1.15 US dollars / euro (150 yen / US dollar, 162 yen / euro, and 1.08 US dollars / euro at the end of the previous consolidated fiscal year).

(3) Analysis of Cash Flows

Cash flows from operating activities for the current consolidated fiscal year resulted in a total income of 98.7 billion yen (versus a total income of 69.8 billion yen for the previous consolidated fiscal year). This was mainly attributable to profit adjusted for non-cash items such as impairment losses, depreciation and other expenses.

Cash flows from investing activities resulted in an expenditure of 39.0 billion yen (versus an income of 52.5 billion yen in the previous consolidated fiscal year). The primary factors included expenditures for capital investments and other activities.

Accordingly, free cash flows, which comprise cash flows from both operating and investing activities, resulted in an income of 59.7 billion yen (versus an income of 122.4 billion yen in the previous consolidated fiscal year).

Cash flows from financing activities resulted in an expenditure of 73.3 billion yen (versus an expenditure of 134.5 billion yen in the previous consolidated fiscal year). This was mainly due to repayments of long-term borrowings and dividend payments, despite proceeds from short-term borrowings.

As a result, with the conversion difference for cash and cash equivalents counted as well, cash and cash equivalents decreased by 3.1 billion yen in the current consolidated fiscal year.

(4) Outlook for FY2026

Under the “Teijin Group Medium-Term Management Plan 2026–2028,” the Group will focus on the strengthening of its revenue base and getting back on a growth track through structural reforms and growth based on Customer-Driven businesses.

In FY2026, the Group will promote its growth strategy in the Customer-Driven businesses centering on Apparel & Industries and Healthcare & Life Solutions, concurrently with establishing a stable and high-quality revenue base by steadily materializing the effects of the ongoing structural reforms. Furthermore, the Group will endeavor to perform sustainable improvement of corporate value by achieving both profitability and capital efficiency through thorough ROIC-oriented management with emphasis on capital cost.

Additionally, the Group will continue to strengthen the management system, such as technology strategy, DX/AX strategy and human capital, to enhance its capability to achieve the goals. The Group will also maintain its financial soundness while simultaneously balancing growth investments and shareholder returns.

The consolidated earnings forecast for the full year of FY2026 is 850.0 billion yen in revenue, 30.0 billion yen in adjusted operating income, and 45.0 billion yen in profit attributable to owners of parent. The forecasts of ROE and ROIC are 12% and 3%, respectively.

The annual average exchange rates used as the basis of the earnings forecasts are 150 yen to the U.S. dollar and 176 yen to the euro.

(Unit: Billions of yen)

	Revenue	Adjusted operating income	Profit attributable to owners of parent
FY2026 (Forecasts) (A)	850.0	30.0	45.0
FY2025 (B)	873.2	25.8	(88.0)
Change in amount (A–B)	(23.2)	+4.2	+133.0
Change (%)	(2.7%)	+16.4%	—

Note: Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

(For reference) Forecast for Segment Results

(Unit: Billions of yen)

	FY2025		FY2026 (Forecasts)	
	Revenue	Adjusted operating income	Revenue	Adjusted operating income
Apparel & Industries	350.1	17.1	400.0	19.0
Healthcare & Life Solutions	138.6	13.4	110.0	10.0
Electronics & Energy	149.9	18.9	150.0	15.0
Specialty Materials	212.8	(9.0)	170.0	3.0
Others	21.9	(3.5)	20.0	(5.0)
Elimination and corporate	—	(11.1)	—	(12.0)
Total	873.2	25.8	850.0	30.0

Note: FY2025 figures based on the new segments are preliminary, pending audit and final calculation.

(For reference) Key management indicators

	FY2025	FY2026 (Forecasts)
ROE	(22.1%)	12%
ROIC	2.6%	3%
Adjusted operating income (Billions of yen)	25.8	30.0

Note:ROE = Profit attributable to owners of parent / Average* of equity attributable to owners of parent

ROIC = Adjusted operating income after tax / Average* of invested capital

(Invested capital: Equity + interest-bearing liabilities)

*Average: ([Beginning balance + Ending balance] / 2)

2. Basic Policy on Selection of Financial Reporting Standards

As we accelerate our global business development, we have adopted International Financial Reporting Standards (IFRS) voluntarily from the first quarter of the fiscal year ending March 31, 2025, to enhance the international comparability of our financial information, improve convenience for our stakeholders, and establish a global management foundation by unifying accounting standards in the Group.

Italicized product and service names in this report are trademarks or registered trademarks of the Teijin Group in Japan and/or other countries, or, where noted, are protected as the trademarks and/or trade names of other companies.

3. Consolidated Financial Statements and Notes Thereto

(1) Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and cash equivalents	107,538	104,474
Trade and other receivables	166,741	167,365
Inventories	227,032	208,820
Other financial assets	8,499	12,179
Other current assets	22,685	20,155
Subtotal	532,496	512,993
Assets held for sale	55,388	15,089
Total current assets	587,883	528,082
Non-current assets		
Property, plant and equipment	250,945	218,141
Right-of-use assets	23,333	19,147
Goodwill	8,334	7,897
Intangible assets	85,511	50,967
Investment property	11,888	10,383
Investments accounted for using equity method	45,602	37,996
Other financial assets	26,481	29,108
Retirement benefit asset	728	905
Deferred tax assets	16,977	13,373
Other non-current assets	3,589	4,116
Total non-current assets	473,389	392,033
Total assets	1,061,272	920,115

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	105,296	103,592
Bonds and borrowings	124,985	129,411
Lease liabilities	7,954	7,583
Other financial liabilities	5,473	10,613
Income taxes payable	3,693	3,730
Provisions	1,798	1,475
Other current liabilities	38,147	43,061
Subtotal	287,347	299,465
Liabilities directly associated with assets held for sale	31,616	2,452
Total current liabilities	318,962	301,917
Non-current liabilities		
Bonds and borrowings	237,494	182,064
Lease liabilities	16,694	17,354
Other financial liabilities	4,729	5,472
Retirement benefit liability	32,375	34,272
Provisions	992	1,007
Deferred tax liabilities	3,268	3,337
Other non-current liabilities	8,215	6,061
Total non-current liabilities	303,768	249,566
Total liabilities	622,731	551,483
Equity		
Share capital	71,833	71,833
Capital surplus	105,708	105,701
Retained earnings	231,726	138,509
Treasury shares	(11,411)	(10,974)
Other components of equity	34,655	58,634
Other comprehensive income associated with assets held for sale	(1,134)	758
Total equity attributable to owners of parent	431,378	364,461
Non-controlling interests	7,164	4,171
Total equity	438,541	368,631
Total liabilities and equity	1,061,272	920,115

**(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Profit or Loss)**

(Millions of yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Continuing operations		
Revenue	1,005,471	873,190
Cost of sales	(814,020)	(711,226)
Gross profit	191,452	161,964
Selling, general and administrative expenses	(270,330)	(231,322)
Other income	12,595	18,102
Other expenses	(5,545)	(19,457)
Operating income (loss)	(71,828)	(70,714)
Finance income	4,115	4,161
Finance costs	(11,378)	(9,468)
Share of profit of investments accounted for using equity method	1,052	1,960
Profit (loss) before tax	(78,038)	(74,060)
Income tax expense	2,291	(13,859)
Profit (loss) from continuing operations	(75,747)	(87,920)
Discontinued operations		
Profit from discontinued operations	106,058	—
Profit (loss)	30,310	(87,920)
Profit (loss) attributable to		
Owners of parent	28,347	(88,003)
Non-controlling interests	1,963	84
Profit (loss)	30,310	(87,920)
Earnings(loss) per share		
Basic earnings (loss) per share		
Continuing operations	(394.39)	(456.33)
Discontinued operations	541.54	—
Total	147.15	(456.33)
Diluted earnings (loss) per share		
Continuing operations	(394.39)	(456.33)
Discontinued operations	541.54	—
Total	147.15	(456.33)

(Consolidated Statements of Comprehensive Income)

For FY2024 and FY2025

(Millions of yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Profit (loss)	30,310	(87,920)
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	638	3,363
Remeasurements of defined benefit plans	743	2,468
Share of other comprehensive income of investments accounted for using equity method	(20)	(14)
Total of items that will not be reclassified to profit or loss	1,362	5,816
Items that may be reclassified to profit or loss		
Effective portion of cash flow hedges	628	(2,435)
Exchange differences on translation of foreign operations	(3,732)	27,243
Share of other comprehensive income of investments accounted for using equity method	487	163
Total of items that may be reclassified to profit or loss	(2,617)	24,970
Total other comprehensive income(loss), net of tax	(1,256)	30,787
Comprehensive income(loss)	29,055	(57,133)
Comprehensive income(loss) attributable to		
Owners of parent	27,099	(57,225)
Non-controlling interests	1,956	91
Comprehensive income(loss)	29,055	(57,133)

(3) Consolidated Statements of Changes in Equity

FY2024

(Millions of yen)

	Equity attributable to owners of parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Share acquisition rights	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance as of April 1, 2024	71,833	103,133	204,174	(11,772)	474	14,541	—
Profit (loss)	—	—	28,347	—	—	—	—
Other comprehensive income	—	—	—	—	—	634	743
Total	—	—	28,347	—	—	634	743
Purchase of treasury shares	—	—	—	(6)	—	—	—
Disposal of treasury shares	—	(39)	—	155	(312)	—	—
Transfer of loss on disposal of treasury shares	—	117	(117)	—	—	—	—
Share-based payment expenses	—	150	—	213	—	—	—
Dividends	—	—	(7,705)	—	—	—	—
Change in treasury shares of parent arising from transactions with non-controlling interests	—	2,347	—	—	—	—	—
Transfer to non-financial assets	—	—	—	—	—	—	—
Transfers to other comprehensive income relating to assets held for sale	—	—	—	—	—	—	—
Change in scope of consolidation	—	—	(408)	—	—	408	—
Transfer from other components of equity to retained earnings	—	—	7,434	—	—	(6,692)	(743)
Other	—	(0)	0	0	—	(0)	—
Total transactions with owners	—	2,575	(795)	361	(312)	(6,284)	(743)
Balance as of March 31, 2025	71,833	105,708	231,726	(11,411)	162	8,891	—

(Millions of yen)

	Equity attributable to owners of parent						
	Other components of equity			Other comprehensive income related to assets held for sale	Total equity attributable to owners of parent	Non-controlling interests	Total equity
	Effective portion of cash flow hedges	Exchange differences on translation of foreign operations	Total				
Balance as of April 1, 2024	332	26,792	42,139	—	409,507	27,252	436,759
Profit (loss)	—	—	—	—	28,347	1,963	30,310
Other comprehensive income	628	(3,254)	(1,248)	—	(1,248)	(7)	(1,256)
Total comprehensive income	628	(3,254)	(1,248)	—	27,099	1,956	29,055
Purchase of treasury shares	—	—	—	—	(6)	—	(6)
Disposal of treasury shares	—	—	(312)	—	(197)	—	(197)
Transfer of loss on disposal of treasury shares	—	—	—	—	—	—	—
Share-based payment transactions	—	—	—	—	363	—	363
Dividends	—	—	—	—	(7,705)	(515)	(8,220)
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	2,347	(2,341)	6
Transfer to non-financial assets	(30)	—	(30)	—	(30)	—	(30)
Transfers to other comprehensive income relating to assets held for sale	—	1,134	1,134	(1,134)	—	—	—
Change in scope of consolidation	—	—	408	—	—	(19,190)	(19,190)
Transfer from other components of equity to retained earnings	—	—	(7,434)	—	—	—	—
Other	—	—	(0)	—	0	2	2
Total transaction with owners	(30)	1,134	(6,236)	(1,134)	(5,228)	(22,044)	(27,272)
Balance as of March 31, 2025	930	24,672	34,655	(1,134)	431,378	7,164	438,541

FY2025

(Millions of yen)

	Equity attributable to owners of parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Share acquisition rights	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance as of April 1, 2025	71,833	105,708	231,726	(11,411)	162	8,891	—
Profit (loss)	—	—	(88,003)	—	—	—	—
Other comprehensive income	—	—	—	—	—	3,349	2,468
Total	—	—	(88,003)	—	—	3,349	2,468
Purchase of treasury shares	—	—	—	(5)	—	—	—
Disposal of treasury shares	—	(25)	—	82	(57)	—	—
Transfer of loss on disposal of treasury shares	—	193	(193)	—	—	—	—
Share-based payment transactions	—	(175)	—	360	—	—	—
Dividends	—	—	(9,640)	—	—	—	—
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	—	—	—
Transfer to non-financial assets	—	—	—	—	—	—	—
Transfers to other comprehensive income associated with to assets held for sale	—	—	—	—	—	(161)	—
Change in scope of consolidation	—	—	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	4,620	—	—	(2,152)	(2,468)
Other	—	(0)	—	—	—	—	—
Total transactions with owners	—	(7)	(5,214)	437	(57)	(2,314)	(2,468)
Balance as of March 31, 2026	71,833	105,701	138,509	(10,974)	105	9,926	—

(Millions of yen)

	Equity attributable to owners of parent						
	Other components of equity			Other comprehensive income related to assets held for sale	Total equity attributable to owners of parent	Non-controlling interests	Total equity
	Cash flow hedges	Exchange differences on translation of foreign operations	Total				
Balance as of April 1, 2025	930	24,672	34,655	(1,134)	431,378	7,164	438,541
Profit (loss)	—	—	—	—	(88,003)	84	(87,920)
Other comprehensive income	(2,435)	27,398	30,779	—	30,779	8	30,787
Total comprehensive income	(2,435)	27,398	30,779	—	(57,225)	91	(57,133)
Purchase of treasury shares	—	—	—	—	(5)	—	(5)
Disposal of treasury shares	—	—	(57)	—	0	—	0
Transfer of loss on disposal of treasury shares	—	—	—	—	—	—	—
Share-based payment expenses	—	—	—	—	184	—	184
Dividends	—	—	—	—	(9,640)	(40)	(9,681)
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	—	—	—
Transfer to non-financial assets	(232)	—	(232)	—	(232)	—	(232)
Transfers to other comprehensive income							
Associated with to assets held for sale	—	(596)	(758)	758	—	—	—
Change in scope of consolidation	—	(1,134)	(1,134)	1,134	—	(3,044)	(3,044)
Transfer from other components of equity to retained earnings	—	—	(4,620)	—	—	—	—
Other	—	—	—	—	—	0	0
Total transactions with owners	(232)	(1,730)	(6,800)	1,891	(9,692)	(3,084)	(12,777)
Balance as of March 31, 2026	(1,736)	50,339	58,634	758	364,461	4,171	368,631

(4) Consolidated Statements of Cash Flows

(Millions of yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Cash flows from operating activities		
Profit (loss) before tax	(78,038)	(74,060)
Profit before tax from discontinued operations	106,601	—
Depreciation and amortization	71,026	60,315
Impairment losses	95,215	88,940
Share of loss (profit) of investments accounted for using equity method	(1,011)	(1,960)
Increase or decrease in retirement benefit asset or liability	(1,012)	4,098
Interest and dividend income	(3,555)	(3,989)
Interest expenses	10,427	6,826
Loss (gain) on sale or disposal of fixed assets	(8,137)	(1,965)
Loss (gain) on sale of shares of affiliates	(102,059)	3,027
Decrease (increase) in trade and other receivables	19,998	8,272
Decrease (increase) in inventories	(10,107)	23,879
Increase (decrease) in trade and other payables	(12,504)	(7,446)
Other	3,907	(2,186)
Subtotal	90,751	103,750
Interest and dividends received	10,608	10,099
Proceeds from insurance income	517	—
Interest paid	(10,285)	(7,304)
Income taxes paid	(21,748)	(7,891)
Net cash provided by (used in) operating activities	69,843	98,654
Cash flows from investing activities		
Purchase of property, plant and equipment	(57,397)	(53,514)
Proceeds from sale of property, plant and equipment	12,155	5,847
Purchase of intangible assets	(4,029)	(6,434)
Purchase of investments	(3,731)	(952)
Proceeds from sale of investment securities	12,058	14,204
Advance receipt from sale of investment securities	—	4,687
Net decrease (increase) in short-term loans receivable	(1,433)	(1,666)
Purchase of shares of subsidiaries resulting in change in scope of consolidation	—	(1,277)
Proceeds from (payments for) sale of shares of subsidiaries resulting in change in scope of consolidation	96,071	1,130
Other	(1,178)	(981)
Net cash provided by (used in) investing activities	52,517	(38,956)

(Millions of yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(56,391)	8,568
Proceeds from long-term borrowings	5,984	—
Repayments of long-term borrowings	(48,543)	(65,915)
Redemption of bonds	(20,090)	—
Repayments of lease liabilities	(7,030)	(6,219)
Purchase of treasury shares	(6)	(5)
Dividends paid to owners of parent	(7,705)	(9,640)
Dividends paid to non-controlling interests	(678)	(40)
Net cash provided by (used in) financing activities	(134,459)	(73,251)
Effect of exchange rate changes on cash and cash equivalents	(1,776)	8,707
Net increase (decrease) in cash and cash equivalents	(13,875)	(4,847)
Cash and cash equivalents at beginning of period	123,212	107,538
Net increase (decrease) in cash and cash equivalents included in assets held for sale	(1,798)	1,782
Cash and cash equivalents at end of period	107,538	104,474

(5) Notes to the Consolidated Financial Statements

(Note on Going Concern Assumptions)

Not applicable.

(Segment Information)

(1) Overview of reportable segments

The Teijin Group's reportable operating segments are the components of the Teijin Group for which separate financial information is available and evaluated regularly by its Board of Directors in determining the allocation of management resources and in assessing performance.

The Teijin Group currently divides its operations into business fields, based on type of product, nature of business, and services provided. For the products and services of each business field, the Teijin Group formulates comprehensive strategies, in Japan and overseas, to drive its business activities forward.

Accordingly, the Teijin Group divides its operations into reportable operating segments on the same basis as it uses internally so the Teijin Group sets the three reportable segments, which are "Materials," "Fibers & Products Converting," and "Healthcare."

"Materials" involves the production and sale of aramid fibers, polycarbonate resin, carbon fibers, and composites, while "Fibers & Products Converting" involves the production and sale of polyester fibers and fiber products, etc. "Healthcare" includes the production and sale of pharmaceuticals and medical devices, etc. and the provision of home healthcare services.

(2) Segment revenue and performance

Results of FY2024 (April 1, 2024, through March31, 2025)

(Millions of yen)

	Reportable segments				Others (Note 1)	Total	Adjustments (Note 2,3)	Consolidated
	Materials	Fibers & Products Converting	Healthcare	Total				
Revenue								
External	459,317	351,923	136,973	948,213	57,259	1,005,471	—	1,005,471
Intersegment	10,735	2,264	4	13,003	4,695	17,698	(17,698)	—
Total	470,052	354,187	136,977	961,216	61,954	1,023,169	(17,698)	1,005,471
Adjusted operating income (Note 4)	6,026	17,842	5,690	29,558	7,082	36,640	(9,046)	27,594
Segment assets	467,531	223,458	198,029	889,018	130,581	1,019,599	41,673	1,061,272
Other items								
Depreciation and amortization	26,506	7,635	29,006	63,147	4,738	67,885	2,751	70,636
Impairment losses	64,017	348	28,804	93,170	1,642	94,812	403	95,215
Equity method investments	563	6,627	13,653	20,843	24,758	45,602	—	45,602
Capital expenditures	23,686	7,219	17,626	48,531	8,671	57,202	2,196	59,398

Note 1. "Others," which includes battery materials & membrane business and regenerative medicine & implantable medical device business, does not qualify.

Note 2. Adjustments of the adjusted operating income of (9,046) million yen include the elimination of intersegment transactions of 81 million yen and corporate expenses of (9,127) million yen. Corporate expenses are mainly expenses related to administrative divisions of the head office that are not attributable to the reportable segments.

Note 3. Adjustments of the segment asset of 41,673 million yen include the elimination of intersegment receivables etc of (49,858) million yen and corporate assets of 91,531 million yen. Corporate assets are mainly surplus funds managed by the parent company (cash and deposit etc) and long-term investment assets (investment securities etc) that are not attributable to the reportable segments.

Note 4. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of

investments accounted for using the equity method.

Results of FY2025 (April 1, 2025 through March31, 2026)

(Millions of yen)

	Reportable segments				Others (Note 1)	Total	Adjustments (Note 2,3)	Consolidated
	Materials	Fiber and Products Converting	Healthcare	Total				
Revenue								
External	338,579	350,068	138,558	827,205	45,986	873,190	—	873,190
Intersegment	10,608	2,483	—	13,091	3,790	16,881	(16,881)	—
Total	349,186	352,551	138,558	840,295	49,776	890,071	(16,881)	873,190
Adjusted operating income (Note 4)	118	17,095	13,427	30,639	4,559	35,198	(9,417)	25,781
Segment assets	374,757	230,997	158,786	764,540	129,530	894,070	26,045	920,115
Other items								
Depreciation and amortization	20,570	7,771	25,724	54,065	3,893	57,958	2,357	60,315
Impairment losses	62,295	249	25,295	87,840	—	87,840	1,100	88,940
Equity method investments	604	6,685	12,989	20,278	17,718	37,996	—	37,996
Capital expenditures	23,178	6,985	19,108	49,271	7,846	57,118	2,488	59,605

Note 1. "Others," which includes battery materials & membrane business and regenerative medicine & implantable medical device business, does not qualify.

Note 2. Adjustments of the adjusted operating income of (9,417) million yen include the elimination of intersegment transactions of 67 million yen and corporate expenses of (9,484) million yen. Corporate expenses are mainly expenses related to administrative divisions of the head office that are not attributable to the reportable segments.

Note 3. Adjustments of the segment asset of 26,045 million yen include the elimination of intersegment receivables etc of (52,612) million yen and corporate assets of 78,656 million yen. Corporate assets are mainly surplus funds managed by the parent company (cash and deposit etc) and long-term investment assets (investment securities etc) that are not attributable to the reportable segments.

Note 4. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

The adjustment from adjusted operating income to profit before tax is as follows:

(Millions of yen)

	FY2024	FY2025
Adjusted operating income	27,594	25,781
Gain on sale of fixed assets	10,622	3,876
Loss on disposal of fixed assets	(2,508)	(1,910)
Impairment losses	(95,215)	(88,940)
Special retirement benefits(Note 1)	(4,665)	(4,008)
Gain (Loss) on sale of shares of subsidiaries and affiliates	—	(3,027)
Share of loss(profit) of investments accounted for using the equity method(Note 2)	(4,729)	(2,704)
Others	(2,926)	219
Operating income (loss)	(71,828)	(70,714)
Finance income	4,115	4,161
Finance costs	(11,378)	(9,468)
Share of profit (loss) of investments accounted for using the equity method	1,052	1,960
Profit (loss) before tax	(78,038)	(74,060)

Note 1. "Special retirement benefits" for FY2024 primarily relate to the Early Retirement Incentive Program, whereas those for FY2025 primarily relate to business structure transformation.

Note 2. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

(3) Information by product/service

Revenue from external customers

(Millions of yen)

	FY2024	FY2025
High-performance materials (Note)	270,930	268,527
Composites	188,387	70,051
Fibers & Products Converting	351,923	350,068
Healthcare	136,973	138,558
Others	57,259	45,986
Total	1,005,471	873,190

Note: The High-performance materials category involves aramid fibers, polycarbonate resin and carbon fibers.

(4) Information by geographical segment

a. Revenue from external customers (Note1)

(Millions of yen)

	FY2024	FY2025
Japan	409,141	395,472
PRC	174,754	170,772
U.S.	182,659	92,074
Asia	89,185	95,409
Americas(ex-U.S.) (Note 2)	37,542	8,482
Europe others (Note 3)	112,190	110,982
Total	1,005,471	873,190

Note 1. Geographical segments are determined based on the country/region of domicile of customers.

Note 2. "Americas" are North American and Latin American countries excluding the United States.

Note 3. "Europe, others" includes the Middle East, Africa and Oceania.

b. Non-current assets (excluding financial assets, deferred tax assets and retirement benefit asset)

(Millions of yen)

	As of March 31, 2025	As of Mar 31, 2026
Japan	215,679	181,290
U.S.	13,496	7,634
Netherlands	78,453	37,668
PRC	21,290	24,207
Asia	28,579	29,944
Europe	26,041	29,842
Americas (ex-U.S.) (Note 1)	61	66
Total	383,600	310,651

Note 1. "Americas" are North American and Latin American countries excluding the United States.

(5) Information by major customer

Omitted as no single customer accounts for more than 10% of consolidated revenue as reported in the Consolidated Statements of Profit or Loss.

(Impairment of Non-Financial Assets)

The Company recognized the impairment loss of 88,940 million yen for the fiscal year ended March 31, 2026. The major items are as follows:

(1) Fixed assets of the Twaron business

An impairment loss of 50,354 million yen was recognized for the fixed assets of Twaron business under the Materials segment. The impairment loss of 42,289 million yen and 8,065 million yen were included in “Cost of sales” and “Selling, general and administrative expenses,” respectively. With regard to the Twaron business, factors such as intensified competition in main applications and the appreciation of the euro, have also had an impact. Consequently, it is now expected that achieving the short-term plan will be difficult. Therefore, indications of impairment were identified, and as a result of an impairment test, the recoverable amount of the fixed assets of the business was determined to be lower than their carrying amounts. Therefore, the impairment loss on the fixed assets was recognized.

(2) Fixed assets of the carbon fibers business

An impairment loss of 8,156 million yen was recognized for the fixed assets of carbon fibers business under the Materials segment. The impairment loss of 7,883 million yen and 273 million yen were included in “Cost of sales” and “Selling, general and administrative expenses,” respectively. As for the carbon fibers business, the supply-demand balance, mainly for general-purpose applications, has continued to soften due to intensified competition, and market prices have continued to decline. As a result, it has become necessary to transform the business structure into one that is less susceptible to changes in the business environment. In this context, as part of a fundamental cost structure reform aimed at stabilizing earnings, the Company decided to review its global production system and temporarily suspend operations at its carbon fiber manufacturing site in the United States. Under these circumstances, indications of impairment were identified in the carbon fibers business in Japan and the United States, and as a result of an impairment test, the recoverable amount of the fixed assets was determined to be lower than their carrying amounts. Therefore, the impairment loss on the fixed assets was recognized.

(3) Sales rights for the type 2 diabetes treatments and fixed assets related to the pharmaceutical business

As stated in the Teijin Group Medium-Term Management Plan 2026-2028 announced in May 2026, and in line with the policy of narrowing to the rare / intractable disease areas in the Healthcare segment as part of structural reforms, the Company conducted impairment tests in the current consolidated fiscal year on the Japan sales rights for a type 2 diabetes treatments and on fixed assets related to the pharmaceutical business.

As a result of these impairment tests, the Company recognized an impairment loss of 25,400 million yen. Of this amount, 2,806 million yen and 22,594 million yen were included in “Cost of sales” and “Selling, general and administrative expenses,” respectively.

(Earnings Per Share)

(1) Basic earnings per share and diluted earnings per share

(Yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Basic earnings per share	147.15	(456.33)
Continuing operations	(394.39)	(456.33)
Discontinued operations	541.54	—
Diluted earnings per share	147.15	(456.33)
Continuing operations	(394.39)	(456.33)
Discontinued operations	541.54	—

(2) Basis of calculating basic earnings per share and diluted earnings per share

(Millions of yen)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Profit attributable to common shareholders of parent	28,347	(88,003)
Continuing operations	(75,978)	(88,003)
Discontinued operations	104,325	—
Profit attributable to common shareholders of parent after adjustment for the effects of dilutive potential shares	28,347	(88,003)
Continuing operations	(75,978)	(88,003)
Discontinued operations	104,325	—

(Thousands of shares)

	FY2024 (Apr. 2024-Mar. 2025)	FY2025 (Apr. 2025-Mar. 2026)
Weighted-average number of common shares	192,645	192,850
Increase in number of common shares by share subscription rights	-	—
Weighted-average number of common shares (diluted)	192,645	192,850

Note. In the previous fiscal year 2024, 153 thousand potentially dilutive common shares were excluded from the calculation of diluted earnings per share due to their anti-dilutive effect.

In the current fiscal year 2025, 86 thousand potentially dilutive common shares were excluded from the calculation of diluted earnings per share due to their anti-dilutive effect.

(Significant Subsequent Events)

(1) Changes in reportable segments

On April 1, 2026, the Company implemented an organizational restructuring.

Through this reorganization, the Company will operate its organizational structure in line with the stage of development of the Customer-Driven business, thereby further deepening this business model. In the materials businesses, the Company will also promote a transformation from a materials-oriented structure to one oriented with customers and applications.

Accordingly, the Company has decided to change its reportable segments from the previous three—"Materials," "Fibers & Products Converting," and "Healthcare"—to four categories—"Apparel & Industries," "Healthcare & Life Solutions," "Electronics & Energy," and "Specialty Materials," effective from the next consolidated fiscal year. Information on the amounts of each item for the reportable segments for the current consolidated fiscal year, based on the revised segments, is currently being calculated.

The principal lines of business of each segment after the change are as follows.

Segments	Lines of business
Apparel & Industries	Production and sale of fiber products, and production and sale of polyester fibers and fabrics, etc.
Healthcare & Life Solutions	Production and sale of pharmaceuticals and medical devices, etc. and the provision of home healthcare services, and production and sale of other healthcare-related products.
Electronics & Energy	Production and sale of resin, battery materials & membrane.
Specialty Materials	Production and sale of aramid fibers, carbon fibers, and composites.

(2) Completion of the transfer of investments that were previously accounted for using the equity method

The Company, pursuant to the share transfer agreement entered into on August 29, 2025 with its co-investor, DuPont de Nemours, Inc. (hereinafter, "DuPont"), transferred all of its shares in DuPont Teijin Advanced Papers (Japan) and DuPont Teijin Advanced Papers (Asia) Limited—jointly controlled entities of the Company and DuPont—to DuPont, effective as of April 1, 2026. As a result, in the first quarter of the fiscal year ending March 31, 2027, the Company expects to record approximately 45.5 billion yen as "Gain on the sale of subsidiary shares" under other income.